CalciMedica, Inc. (NASDAQ:CALC) Sees Large Decrease in Short Interest

CalciMedica, Inc. (NASDAQ:CALC) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 61,300 shares, a decrease of 6.6% from the December 31st total of 65,600 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average daily volume of 59,400 shares, the short-interest ratio is presently 1.0 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a report on Thursday, November 14th.

Hedge Funds Weigh In On CalciMedica

Several institutional investors and hedge funds have recently modified their holdings of the business. PVG Asset Management Corp acquired a new position in shares of CalciMedica during the 3rd quarter worth about $67,000. Atria Investments Inc raised its holdings in shares of CalciMedica by 136.5% during the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after acquiring an additional 15,296 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of CalciMedica by 51.2% in the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after purchasing an additional 22,525 shares during the period.

CalciMedica Price Performance

CALC traded up $0.08 on Monday, reaching $2.64. 132,582 shares of the stock were exchanged, compared to its average volume of 28,456. CalciMedica has a fifty-two week low of $2.05 and a fifty-two week high of $6.26. The firm has a market capitalization of $35.59 million, a PE ratio of -2.44 and a beta of 1.22. The company’s 50-day moving average price is $2.99 and its 200 day moving average price is $3.72.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.